Novo Nordisk will broaden its cardiometabolic pipeline by pairing up with machine learning and drug discovery startup Valo Health in a deal that builds on the Danish pharma’s stature in the growing field.
In exchange for $60 million upfront and in near-term payments, Novo will get its hands on three cardiovascular assets created by Valo’s computational work, the companies said Monday morning.
Nearly $2.7 billion in milestone payments are on the line for up to eight more programs in the deal with Boston-based Valo, and it will pay for R&D work and could dole out royalties, should any programs make it to market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.